FLOXIN
LOE ApproachingNDAORALTABLET
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOXIN is an oral small-molecule tablet approved in 1990 by Johnson & Johnson. The specific mechanism of action and therapeutic indications are not specified in available data. This is a mature NDA product approaching loss of exclusivity.
LOE Approaching
LOE-approaching status signals shrinking team resources and commercial focus shifting to retention and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children
Started Nov 2002
96 enrolled
Otitis Media
Career Relevance
Zero linked job openings indicate minimal active hiring; roles focus on legacy management and operational efficiency rather than growth. Career growth on this product is limited; professionals should expect restructuring and transition opportunities as LOE approaches.
Brand Manager
Worked on FLOXIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.